Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial

AIMS: This phase 2, double‐blind, randomized, placebo‐controlled trial (http://clinicaltrials.gov NCT02702011) with 4 sites in Japan investigated the pharmacodynamics (PD), pharmacokinetics (PK) and safety profile of empagliflozin in Japanese participants with type 1 diabetes mellitus (T1DM) as adju...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Diabetes Obes Metab
Главные авторы: Shimada, Akira, Hanafusa, Toshiaki, Yasui, Atsutaka, Lee, Ganghyuck, Taneda, Yusuke, Sarashina, Akiko, Shiki, Kosuke, George, Jyothis, Soleymanlou, Nima, Marquard, Jan
Формат: Artigo
Язык:Inglês
Опубликовано: Blackwell Publishing Ltd 2018
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6099358/
https://ncbi.nlm.nih.gov/pubmed/29766633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13351
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы